Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non–Small-Cell Lung Cancer

This publication has 24 references indexed in Scilit:

• Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany
  Lung Cancer, 2013
• Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer
  New England Journal of Medicine, 2013
• ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
  Journal of Clinical Oncology, 2012
• Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
  Journal of Thoracic Oncology, 2011
• A qualitative exploration of a respiratory distress symptom cluster in lung cancer: Cough, breathlessness and fatigue
  Lung Cancer, 2011
• Assessing Coughing and Wheezing in Lung Cancer: A Pilot Study
  Oncology Nursing Forum, 2004
• Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
  Journal of Clinical Oncology, 2004
• Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews
  BMJ, 1998
• Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment
  British Journal of Cancer, 1995
• The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
  JNCI: Journal of the National Cancer Institute, 1993